Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial
Hofsø, Dag; Fatima, Farhat; Borgeraas, Heidi; Birkeland, Kåre I.; Gulseth, Hanne Løvdal; Hertel, Jens Kristoffer; Johnson, Line Kristin; Lindberg, Morten; Nordstrand, Njord; Småstuen, Milada Cvancarova; Stefanovski, Darko; Svanevik, Marius; Valderhaug, Tone Gretland; Sandbu, Rune; Hjelmesæth, Jøran
Journal article, Peer reviewed
Accepted version
Date
2019-10-30Metadata
Show full item recordCollections
Original version
Hofsø D, Fatima F, Borgeraas H, Birkeland KI, Gulseth HL, Hertel J, Johnson LK, Lindberg M, Nordstrand N, Småstuen MC, Stefanovski D, Svanevik M, Valderhaug TG, Sandbu R, Hjelmesæth J. Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial. The Lancet Diabetes and Endocrinology. 2019;7(12):912-924 https://dx.doi.org/10.1016/S2213-8587(19)30344-4Abstract
Background: The comparative effectiveness of various bariatric procedures on remission of type 2 diabetes
remains debated. We aimed to compare the two most commonly used procedures, hypothesising
higher remission rates of diabetes after gastric bypass than after sleeve gastrectomy.
Methods: The Oseberg study is an ongoing triple-blind, randomised, single-centre trial taking place at Vestfold
Hospital Trust, Norway. Adult patients with type 2 diabetes and obesity were randomly assigned (1:1)
to receive either gastric bypass or sleeve gastrectomy. Randomisation was performed with a
computerised random number generator using block sizes of 10. Treatment allocation was concealed
using sealed opaque envelopes, and was masked from participants, study personnel and outcome
assessors. Primary outcomes were, first, the proportion of participants with complete remission of
diabetes; glycated haemoglobin 6·0% (42 mmol/mol) or less with no diabetes medication, and,
second, beta-cell function modelled from an intravenous glucose tolerance test at one year. Analyses
were performed according to intention-to-treat and per-protocol principles. The trial is registered at
ClinicalTrials.gov with identifier: NCT01778738.
Findings: Between January 28, 2013 and February 4, 2018, 109 patients were randomly assigned to gastric
bypass (n=54) or sleeve gastrectomy (n=55), with a total of 107 (98%) patients completing 1-year
follow-up. Remission of diabetes occurred in 40/53 patients (75%) in the gastric bypass-group and
26/54 patients (48%) in the sleeve gastrectomy-group; risk ratio 1·57, 95% CI 1·14–2·15; p=0·0036.
Beta-cell function increased 6- to 7-fold from baseline, with no differences between groups. The
number of early and late complications after gastric bypass and sleeve gastrectomy were 10 versus 8
and 17 versus 22, respectively.
Interpretation: Gastric bypass being found to be superior to sleeve gastrectomy for remission of type 2 diabetes
might have important individual and societal implications, including the potential to improve
diabetes care and reduce related societal costs.
Publisher
ElsevierLancet